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PolymerAcute respiratory distress syndrome (ARDS) is an inﬂammatory condition that can be associated with
capillary leak of serum into alveoli causing inactivation of surfactant. Resistance to inactivation is affected by
types and concentrations of surfactant proteins, lipids, and polymers. Our aim was to investigate the effects of
different combinations of these three components. A simple lipid mixture (DPPC/POPG) or a more complex
lipid mixture (DPPC/POPC/POPG/cholesterol) was used. Native surfactant proteins SP-B and SP-C obtained
from pig lung lavage were added either singly or combined at two concentrations. Also, non-ionic polymers
polyethylene glycol and dextran and the anionic polymer hyaluronan were added either singly or in pairs
with hyaluronan included. Non-ionic polymers work by different mechanisms than anionic polymers, thus
the purpose of placing them together in the same surfactant mixture was to evaluate if the combination would
show enhanced beneﬁcial effects. The resulting surfactant mixtures were studied in the presence or absence
of serum. A modiﬁed bubble surfactometer was used to evaluate surface activities. Mixtures that included
both SP-B and SP-C plus hyaluronan and either dextran or polyethylene glycol were found to be the most
resistant to inhibition by serum. These mixtures, as well as some with either SP-B or SP-C with combined
polymers were as or more resistant to inactivation than native surfactant. These results suggest that improved
formulations of lung surfactants are possible and may be useful in reducing some types of surfactant
inactivation in treating lung injuries.pital, Department of Pediatrics,
USA. Tel.: +1 415 206 3080;
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The normal functioning of pulmonary surfactant is critical for gas
exchange. There are several important functions of lung surfactant.
It lowers the work of breathing by reducing the effort needed to
breathe in sufﬁcient air for gas exchange to occur. It maintains pa-
tency of alveoli during inspiration and expiration, thereby allowing
for continued gas exchange during low lung volumes. In addition, it
provides an anti-infectious, anti-inﬂammatory surface exposed to the
environment [1,2]. Acute respiratory distress syndrome (ARDS) is a
serious complication resulting from various acute lung injuries.
Treatment of premature infants with neonatal RDS using animal-
derived pulmonary surfactants is dramatically effective [3], but (with
the possible exception of children [4]) is ineffective in ARDS [5].
A growing body of work [6] shows that inactivation of surfactant
activity may explain in part why surfactant treatment has been
ineffective in ARDS. Surfactant inactivation is a broad term for theinability of surfactant under a variety of conditions to provide a
normal low surface tension. The term covers degradation, alteration
of subphase or surface structures, or interference with surfactant
adsorption or surface compression. Inhibition may be deﬁned as an
interference of the normal functioning of surfactant, and may be seen
as one speciﬁc example of inactivation. Inhibition may be caused in
vitro and in vivo by serum proteins, secretory phospholipase A2,
cholesterol and/or other inﬂammatory products [7–9]. This hypoth-
esis has led to attempts to formulate surfactants more resistant to
inhibition than those in current clinical use.
Surfactant proteins, as well as the composition and amount of
various surfactant lipids, contribute to reducing susceptibility to
inhibition. In general, surfactants rich in the two hydrophobic
surfactant proteins are less susceptible than those with lower
concentrations [10,11]. Surfactants in clinical use are derived from
animal lungs and contain variable amounts of two hydrophobic
proteins (SP-B and SP-C) but lack the hydrophilic surfactant proteins,
including SP-A, which is also important in reducing inhibition [12,13].
We and others have found that various ionic and non-ionic
polymers such as hyaluronan (HA), chitosan, polymyxin B, polyeth-
ylene glycol (PEG), or dextran can enhance the surface activity of a
number of surfactants in the presence of inactivating substances such
as serum, albumin, or meconium [6,14–23].
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importance of the type and amount of the two hydrophobic surfactant
proteins (SP-B and SP-C), polymers, and lipids for resistance to serum
induced inhibition. Serum was used because of its relevance to the
pathogenesis of ARDS in which serum leakage into alveoli occurs.
Because SP-B and SP-C are important for the function of surfactant in
situ [24,25,1,2], we assess their effects, singly or combined, in either of
two concentrations. In this study, we used two lipid mixtures, one
simple and one more complex to assess the importance of surfactant
lipid composition on surfactant function [26]. The anti-inhibitory
effects of non-ionic polymers like PEG and dextran occur mainly by
depletion and osmotic forces, while HA forms networks and can
establish electrostatic interactions with lipids and proteins [27–30].
Since these polymers differ substantially from each other in structure,
mechanism, and effect on surfactant, we have chosen to study them
singly or paired with HA. For comparison, native surfactant, with its
full complement of surfactant proteins, isolated from adult porcine
lung lavage was used as a reference standard.
2. Methods
2.1. Materials
Lipids were purchased from Avanti Polar Lipids Inc. (Alabaster,
Alabama). Hyaluronan (HA) 1240 kDa (molecular weight range
850 kDa to 1600 kDa), polyethylene glycol (PEG) 10 kDa (molecular
weight range 8.5 kDa to 11.5 kDa) and dextran 148 kDa (molecular
weight range 90 kDa to 210 kDa) were purchased from Sigma
(St. Louis, MO). The HA preparations were isolates from streptococ-
cus fermentation and all polymers were used as supplied. Native
surfactant and the hydrophobic surfactant proteins, SP-B and SP-C,
were isolated from porcine lung lavage as previously described
[31,32].
2.2. Lipid and lipid/protein mixtures
Two lipid mixtures were compared. The simple lipid mixture
(SLM) was dipalmitoyl phosphatidylcholine/palmitoyloleoyl phos-
phatidylglycerol (DPPC/POPG), 7:3 (w/w); lipids contained in clinical
surfactants [13,33]. A more complex lipid mixture (CLM), composed
of DPPC, palmitoyloleoyl phosphatidylcholine (POPC), POPG, and
cholesterol (52:26:16:5, w/w/w/w), was used to mimic more closely
the balance of the sterol, saturated/unsaturated phospholipids, and
zwitterionic/anionic phospholipids contained in native surfactant.
Each lipid was dissolved in a chloroform/methanol 2:1 solution with
the concentration of the phospholipids veriﬁed by phosphorous assay.
The surfactant proteins B and C were added to the lipid mixtures in
the following concentrations: SP-B 2%; SP-C 2%; SP-B 1%+SP-C 1%;
and SP-B 2%+SP-C 2% (all w/w with respect to phospholipid). These
concentrations approximate those found in surfactants obtained from
animal lungs [13,34]. SLM or CLM with no added surfactant proteins
was also used.
The lipid–protein mixtures were dried under nitrogen and the
dried ﬁlms were suspended by Vortex in 2.5 mM HEPES, 0.9% NaCl,
and 2.5 mM CaCl2 and adjusted to a pH of 7.0. The ﬁnal concentration
was 1.25 mg phospholipid/mL. The samples were then placed in a
45 °C water bath for 1 h and mixed by Vortex every 10 min then
stored at 4 °C for use the next day.
2.3. Addition of polymers
Dry polymers were added singly to thesemixtures in the following
concentrations: HA 0.25%, PEG 5%, and dextran 5% (w/v). The
concentrations of polymer were chosen from previous studies
[8,20,35]. We also added combinations of charged and uncharged
polymers (HA+dextran or HA+PEG) using the above concentrationsand also at half concentration for HA+dextran or HA+PEG. The
mixtures were dispersed by Vortex in 5-s bursts for 1–2 min until
uniform in appearance at room temperature. These mixtures were
studied within 30 min.
2.4. Serum inhibition
Serum, at a protein concentration of 580 mg/mL, was obtained
from exchange transfusions done on newborn infants and pooled then
frozen at −20 °C until needed. It was then thawed and added to the
surfactant mixtures (1.25 mg phospholipid/mL) in varying amounts
to provide a range of serum concentrations relative to surfactant. The
serum/surfactant combinations were mixed by Vortex for 20 s before
testing (within 30 min). The lowest amount of serum protein per mL
of surfactant mixture that caused minimum surface tension after
5 min of cycling (γmin 5 min) to exceed 7 mN/m was deﬁned as the
threshold for inhibition. Total serum protein was added in increments
of 290 μg to determine the threshold for inhibition of each surfactant
mixture. The ﬁnal concentrations of serum protein used in surfactant
ranged from 290 to 5220 μg/mL. Use of human serum was approved
by the University of California Clinical Research Committee.
2.5. Surface activity measurements
Surface activities were measured in a modiﬁed pulsating bubble
surfactometer (MPBS, Electronetics, Buffalo, NY) using a technique to
prevent wetting of the capillary tube in the sample chamber [36]. The
temperature of the 25 μL sample chamber wasmaintained at 37 °C. The
device was calibrated both electronically and with a water manometer.
Measurements were also validated using pure ﬂuids with known
surface tensions. In this study we chose to use the MPBS because this
technique allows relatively rapid testing of a large number of samples
using reasonable amounts of material under physiological conditions of
temperature and compression–expansion rates.
Five replicates from each surfactant mixture were measured and
the results averaged. The following indices of surface activity were
compared for the different mixtures:
1. Surface tension 40 s after initial formation of a static bubble,
deﬁned as “adsorption”.
2. Minimum surface tensionmeasured after cycling for 30 s (10 cycles
of inﬂation/deﬂation): γmin 10th.
3. Maximumsurface tensionmeasured after cycling for 30 s (10 cycles
of inﬂation/deﬂation): γmax 10th.
4. Minimum surface tension after 5 min of inﬂation/deﬂation: γmin
5 min.
5. Maximum surface tension after 5 min of inﬂation/deﬂation: γmax
5 min.
6. The percentage of surface area reduction of the bubble (from
maximum) required for the surface tension to fall to 10 mN/m: A10.
It is an estimate of surface ﬁlm compressibility after 5 min of
inﬂation/deﬂation. A low value indicates that the surface ﬁlm is
relatively non-compressible. If the surface tension did not fall to
≤10 mN/m after maximum surface compression (that is when the
minimum bubble radius of 0.4 mm allowed by the apparatus was
reached), a limit of N47% was assigned, corresponding to the
difference in area between maximum and minimum bubble sizes.
2.6. Analyses
The data are presented as means±SEM. Measurements were
analyzed by one way analysis of variance (ANOVA) using SigmaPlot
software (SPSS Science, Chicago, IL). Comparisons between pairs of
groups were done using the Student–Newman–Keuls method or the
Kruskal–Wallis test when necessary to correct for multiple compar-
isons. A p value≤0.05 was considered statistically signiﬁcant.
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3.1. Comparison of lipid mixtures, SLM and CLMwithout surfactant proteins
The two lipid mixtures (SLM or CLM) in the absence of surfactant
proteins or polymers did not differ signiﬁcantly on any of the
measures of surface activity (Fig. 1). All measures for both lipid
mixtures were signiﬁcantly less surface active than native surfactant.
Adding polymers singly or in combination did not change the surface
activities of the lipid mixtures (data not shown). Since these mixtures
already showed poor surface activity, adding serum was moot.SLM
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Fig. 1. a and c. Surface activities are shown for simple (SLM) (a) and complex (CLM) (c) lip
From left to right, the bars indicate means for samples containing lipid alone, lipid with 2%
indicates statistically signiﬁcant difference from the behavior of lipid alone as determined by
the percentage surface area reduction from themaximum for simple (SLM) (b) and complex
of SP-B and/or SP-C. The asterisk indicates statistically signiﬁcant differences from the behav
ﬁve replicates±SEM.3.2. Comparison of lipid mixtures (SLM and CLM) with added surfactant
proteins: SP-B and/or SP-C with no polymer no serum
Fig. 1 shows results when surfactant proteins were added to each
of the two lipid mixtures. Addition of either surfactant protein
signiﬁcantly improved surface activity but results did not differ
signiﬁcantly between SLM and CLM. Combinations of SP-B+SP-C
tended to result in the best overall surface activity. For example,
SP-B 2%+SP-C 2% in CLM was signiﬁcantly better than SP-B 2%
in CLM for minimum surface tension at 5 min and for A10 (pb0.05,
Fig. 1).SLM
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id mixtures in the absence or presence of different concentrations of SP-B and/or SP-C.
SP-B, with 2% SP-C, with 1% SP-B+1% SP-C, and with 2% SP-B+2% SP-C. The asterisk
single ANOVA, multiple comparison. Means are from ﬁve replicates±SEM. b and d. A10,
(CLM) (d) lipid mixtures is shown in the absence or presence of different concentrations
ior of lipid alone as determined by single ANOVA, multiple comparison. Means are from
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plus 1% SP-C and no serum
With 1% SP-B plus 1% SP-C, adding polymers singly or in com-
bination improved surface activities. For example, with SLM, A10 was
reduced three to sevenfold for mixtures containing HA, HA+dextran,
or HA+PEG compared to native surfactant mixtures, or ten to twenty-
fold compared with mixtures not containing polymers (Table 1). With
CLM, A10 was reduced 1.5 to fourfold for mixtures containing HA,
HA+dextran, or HA+PEG compared with native surfactant, and
two to ﬁvefold for mixtures not containing polymers (Table 1).
In general, the presence of HA, either alone or in combination with
dextran or PEG, was most effective in producing low minimum
surface tensions with minimal compression. At the same time,
maximum surface tensions were generally increased when HA was
added to surfactant mixtures. The increase in maximum surface
tension associated with HA was greater with SLM than with CLM.
3.4. Addition of polymers to lipid mixtures with 2% SP-B, 2% SP-C and no
serum
To establish whether the combined effect of surfactant proteins
and polymers depended on protein concentration, we also tested
samples containing 2% SP-B and/or 2% SP-C. When only SP-B or SP-C,
was added to SLM or CLM, surface activities were affected most in
the mixtures that contain HA+PEG or HA+dextran (Table 2). These
results were similar to those found using mixtures containing 1%
SP-B+1% SP-C (Table 1).
When 2% SP-B+2% SP-C was added to SLM with polymers singly
or in combination, results were similar to results with 1% SP-B+1%
SP-C except that γmax 10th was lower for mixtures containing HA or
HA+dextran, and A10 was higher for these mixtures (Tables 1 and 2).
When 2% SP-B+2% SP-C was added to CLM, with HA alone or in
combination with dextran or PEG, surface activities were improved
compared to those observed in the absence of polymers. For example, A10
was reduced three to fourfold for mixtures containing HA, HA+dextran,
or HA+PEG compared with mixtures of native surfactant or lipid
mixtures with surfactant proteins not containing polymers (Table 2).
3.5. Serum inhibition of lipid/surfactant protein mixtures with and
without polymers
A summary of serum inhibition for all the samples is shown in
Table 3. The minimal serum concentration at which inhibition occursTable 1
Effect of polymers on surface activity of simple lipid mixtures (SLM) and complex lipid mixtu
are means±SEM for ﬁve replicates. An asterisk indicates the value is signiﬁcantly different
comparison.
SLM
No polymer HA PEG De
Adsorption (mN/m) 22±0.4 22±0.6 20 ±0.2* 20
γmin (mN/m) 10th cycle 12±1 0±0* 8±1 2
γmax (mN/m) 10th cycle 32±0.8 54±2* 27±0.6* 28
γmin (mN/m) 5 min 9±2 0±0.1* 0.2±0.2* 0
γmax (mN/m) 5 min 31±0.5 48±2* 27±0.4* 27
A10 41±3 2±0.5* 22±0.7* 19
CLM
No polymer HA PEG De
Adsorption (mN/m) 21±0.3 22±0.5 20±0.2 21
γmin (mN/m) 10th cycle 14±0.9 7±1* 12.2±1 12
γmax (mN/m) 10th cycle 29±0.5 34±1* 28±0.1 29
γmin (mN/m) 5 min 5±1 0.8±0.8 5±1.3 3
γmax (mN/m) 5 min 30±0.6 35±0.6* 29±0.7 31
A10 33±2.3 17±3* 33±2 29is shown for each mixture as a multiple of the lowest serum protein
concentration used (290 μg/mL).
With either SP-C or SP-B only: With only SP-C in the lipid mixture,
the addition of any single polymer had no effect on inhibition. With
only SP-B, the addition of any single polymer was slightly better with
SLM compared to CLM. When HA plus PEG or dextran was added, the
CLM mixtures were usually better than the SLM. It should be noted
that results with anionic and non-ionic polymers combined gave
substantial improvement to resistance to inhibition, especially the
combination of HA and dextran in CLM, where the effect with
surfactant protein was either equal to or superior to native surfactant
(Table 3).
With both SP-B and SP-C: With both surfactant proteins present,
and either PEG or dextran, the SLM mixtures were more resistant to
inhibition than the CLM mixtures. However, in the presence of HA or
HA combined with either nonionic polymer, the CLM mixtures were
comparable to or better than the SLM mixtures. Mixtures containing
combined polymers and combined surfactant proteins were the most
resistant to inhibition by serum. For example, under these conditions,
even in the presence of the highest serum concentrations used
(5220 μg/mL serum protein—18 times the lowest inhibitory concen-
tration) inhibition did not occur (Table 3). For comparison, the
threshold for native surfactant inhibition, tested under identical
conditions, was 3480 μg/mL serum protein or a factor of 12 above the
minimum.
Since mixtures with HA alone or combined with PEG or dextran
were the most resistant to inhibition with serum, more detailed
results for these experiments are presented in Fig. 2. This ﬁgure shows
the effect of increasing concentrations of serum on some measures of
surface activity for SLM or CLM containing 2% SP-B and 2% SP-C, with
or without HA alone, or in combination with dextran or PEG. In the
absence of polymer, lipid/surfactant protein mixtures reached low
minimum surface tension only in the presence of low concentrations
of serum protein (see left panels, Fig. 2). If the samples contained a
combination of HA and PEG, or HA and dextran, the concentration of
serum required to produce inhibition was much higher, reﬂecting the
improved ability of combinations of non-ionic and anionic polymers
to impart resistance to inhibition.
Susceptibility to inhibition was also analyzed with regard to ﬁlm
compressibility (right panels in Fig. 2). Increasing concentrations of
serum increased compressibility (increased A10). In the presence of
HA alone or combined, a low compressibility was achieved even in the
presence of substantial amounts of serum, for both SLM and CLM
(with surfactant proteins). The low ﬁlm compressibility with HAres (CLM) containing 1% SP-B and 1% SP-C. (Abbreviations deﬁned in Methods.) Values
from that for the mixture with no polymer (ﬁrst column). pb0.05 by ANOVA multiple
xtran HA/PEG HA+dextran Native surfactant (no polymer)
±0.2* 21±0.2* 20±0.2* 20±0.2
±0.5* 1±0.3* 0.4±0.2* 10±0.7
±0.2* 38±1* 46±3* 30±0.7
±0.1* 0±0.1* 0±0.1* 2±0.6*
±0.2* 34±0.5* 43±2* 30±0.5
±0.6* 7±1* 3±0.7* 23±2*
xtran HA/PEG HA/dextran Native surfactant (no polymer)
±0.2 20±0.2 21±0.3 20±0.2*
±1.2 6±1* 5±1* 10±0.7
±0.8 33±1* 40±1* 30±0.7
±0.8 1±0.5 1±0.8 2±0.6
±1.3 31±1.5 40±1* 30±0.5
±1 10±0.2* 6±0.6* 23±2
Table 2
Effect of polymers on surface activity of simple lipid mixtures (SLM) and complex lipid mixtures (CLM) containing 2% SP-B and 2% SP-C. (Abbreviations deﬁned in Methods.) Values
are means±SEM for ﬁve replicates. An asterisk indicates the value is signiﬁcantly different from that for the mixture with no polymer (ﬁrst column). pb0.05 by ANOVA multiple
comparison.
No polymer HA PEG Dextran HA/PEG HA/dextran Native surfactant (no polymer)
SLM
Adsorption (mN/m) 23±0.7 21±0.4* 20±0.2* 20±0.2* 20±0.3* 21±0.3* 20±0.2*
γmin (mN/m) 10th cycle 10±0.8 2.4±1* 5±1.6 6±1 2±1* 1±0.9* 10±0.7
γmax (mN/m) 10th cycle 29±0.4 36±1* 28±0.4 29±0.4 37±2* 40.6±1* 30±0.7
γmin (mN/m) 5 min 1.4±1 0±0 1.2±1 0.6±0.4 0±0 0±0 2±0.6
γmax (mN/m) 5 min 28.4±0.4 36±1* 29±0.4 29±0.6 36±1.6* 37±0.8* 30±0.5
A10 25±3 14±1* 19±1.3 24±2 11±1.8* 8±0.7* 23±2
CLM
Adsorption (mN/m) 20±0.4 21±0.2 21±0.4 20±0.2* 21±0.2 21±1 20±0.2
γmin (mN/m) 10th cycle 11±2 4±1* 15±0.9 12±0.4 5±0.5* 2±0.7* 10±0.7
γmax (mN/m) 10th cycle 26±0.7 41±0.8* 26±1 25±0.4 37±0.6* 43±1* 30±0.7
γmin (mN/m) 5 min 1.4±0.5 1.7±0.8 10±1* 5±1.2 1.3±0.5 1.3±0.5 2±0.6
γmax (mN/m) 5 min 27±0.8 42±1* 28±0.2 25±0.2* 38±1* 40±1* 30±0.5
A10 25±3 6±0.7* 43±2.4* 26±2.4 7±0.5* 7±1* 23±2
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higher maximum surface tensions (central panels in Fig. 2).3.6. Lipid/surfactant protein mixtures with lower concentrations of
polymers with and without serum
To ﬁnd whether lower concentrations of polymers would be as
effective as those used in the above studies, we tested CLM or SLM
with 2% SP-B and 2% SP-C with 0.125% HA+2.5% dextran or 2.5% PEG.
Without serum, minimum surface tensions were almost always
higher than mixtures with double these polymer concentrations and
A10 was always signiﬁcantly higher (pb0.05). These mixtures were
also inhibited by serum at concentrations a factor of 3 to 8 lower than
the maximum used with full polymer concentrations which were still
not inhibited (data not shown). The resistance to inhibition for the
lower concentration polymers was essentially the same as those
found with full strength single ionic polymers PEG or dextran.4. Discussion
A major ﬁnding of this study is that SP-B and SP-C combined with
HA and either PEG or dextran, when added to relatively simple lipidTable 3
Effect of protein and polymer composition on the susceptibility to serum inhibition of
simple lipid mixtures (SLM) and complex lipid mixtures (CLM). The concentrations of
serum protein (in multiples of 290 μg/mL) required to cause inhibition are shown.
Polymer Protein
B
2%
C
2%
B+C
1%
B+C
2%
SLM
None 1 1 1 2
HA 4 1 6 6
PEG 2 1 6 6
Dextran 2 1 6 6
HA+PEG 8 4 N18 N18
HA+dextran 10 4 N18 N18
CLM
None 1 1 2 3
HA 3 1 10 10
PEG 1 1 2 1
Dextran 1 1 3 3
HA+PEG 6 12 N18 N18
HA+dextran 14 12 N18 N18mixtures, exhibited less susceptibility to inhibition by serum than any
other mixtures studied including native surfactant.
The mechanisms whereby surfactant proteins and combinations of
polymers interact to prevent or reduce inhibition are complex. The
non-ionic polymers PEG and dextran are believed to act mainly by
depletion and osmotic forces in surfactant mixtures. In contrast, HA
has been reported to establish interactions with itself forming a three
dimensional network in addition to promoting depletion forces.
Zasadzinski has suggested that depletion forces may promote
association of large surfactant structures with the surface, overcoming
the electrostatic barrier imposed by serum proteins that adsorb
quickly to the interface [37], while the presence of surfactant proteins
would be required for the transfer of surface active lipids to the actual
interface and monolayer formation [1,34,38]. These differences in
polymer interactions suggest that substantial additive effects should
occur when both charged (HA) and uncharged (dextran or PEG)
polymers are included with lipid/surfactant protein mixtures, as we
have found.
Cooperative action between surfactant proteins and polymers may
be established by their concerted action at different stages of interfacial
lipid ﬁlm formation and reformation. Polymer-promoted depletion
forces also favor establishment of membrane–membrane contacts and
formation of large surfactant aggregates. Polymers would then stabilize
membrane–membrane and membrane–monolayer contacts and allow
surfactant proteins to catalyze mobilization of phospholipids. Though
the maximum protective effect of polymers was found with surfactant
mixtures containing both surfactant proteins, mixtureswith either SP-B
or SP-C alone, with HA and dextran, could be as or more resistant to
inhibition than native surfactant.
It is remarkable that HA exerts its counter-inhibitory action at
much lower concentrations than the other polymers. HA forms
networks in aqueous solutions [39], and we have shown that HA
promotes formation of such networks in the presence of surfactant
[28]. These charged networks formed by high molecular weight HA
may impose spatial restrictions on the large surfactant aggregates,
which might also contribute entropically to impel surfactant struc-
tures toward the interface [28]. Pasquali-Ronchetti et al. have shown
that HA can interact with phospholipids to form various complexes
which depend on the molecular weight of HA. Phospholipids in the
presence of HA tend to form aggregates [29]. On the other hand,
binding of HA to albumin has been also reported by a number of
investigators. Gramling et al. infer from electrophoretic mobility
studies that HA forms stable complexes with albumin [40]. Gold et al.
have found HA and other glycosaminoglycans binding to columns of
albumin–agarose [41]. If HA binds with albumin, surfactant inhibition
would be reduced since these larger structures would have more
Fig. 2. Three measures of surface activity are compared for simple (SLM) or complex (CLM) lipid mixtures containing 2% SP-B and 2% SP-C as a function of the concentration of serum
in the subphase. HA±PEG or dextran was added to some mixtures. Minimum (γmin) (left panels) and maximum (γmax) (central panels) surface tensions after 5 min of cycling, and
the percent of surface area reduction required to reach surface tensions below 10 mN/m (A10 right panels) for various mixtures have been plotted versus the concentration of added
serum protein for samples without polymers (closed circles), with HA (open circles), with HA and PEG (squares), or with HA and dextran (triangles). Data points are means±SEM
after averaging ﬁve replicates. Shaded areas were drawn to guide the eye.
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surfactant by serum components and counter-inhibition by HA may
depend on the relative afﬁnities of the three components in the
complex surfactant/serum/HA scenario and the consequences on the
reorganization of surfactant structures in the subphase. High
molecular weight HA, along with other glycosaminoglycans, is a
normal constituent in alveolar ﬂuid [42,43] and may play a role in
vivo. Lung injury may also include a signiﬁcant impairment of the
structure and composition of this alveolar glycopolymeric matrix,
which might be restored by supplementation with exogenous
surfactant/HA combinations.
In the absence of serum, an important difference between the
effects of HA vs. PEG or dextran is that HA reduces compressibility of
SLM and CLM to values less than those for ﬁlms formed by native
surfactant (Tables 1 and 2). In the presence of HA, either alone or in
combination with other polymers, little compression is required for
the ﬁlms to reach the lowest surface tensions (Fig. 2). This effectwould reinforce that of SP-B, which stabilizes mechanically com-
pressed ﬁlms, impeding their collapse and reducing the compress-
ibility of the ﬁlms, allowing them to reach low surface tensions with
little compression [34]. We speculate that the HA network matrix
modiﬁes the rheological properties of the subphase, which in turn
affects the surfactant adsorbed to the interface, making it less prone to
fold and collapse, resulting in high lateral pressures (low surface
tensions). In support of this concept, others have found that the
viscoelastic properties of the bulk subphase can produce dramatic
differences in the collapse properties of compressed surface layers
[44]. HA-promoted exclusion of surfactant complexes from the bulk
phase that leads to improved adsorption and effective displacement of
serum components from the interface could then also prevent folding
of compressed ﬁlms into the subphase. Paradoxically, the effect of
HA in preventing folding of interfacial ﬁlms during compression
may also impair re-spreading of compressed ﬁlms during expansion.
In the presence of HA, all surface ﬁlms exhibit relatively high
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usually interpreted as an expression of the efﬁciency of surfactant
ﬁlms to re-spread and reﬁll the expanding interface, which depends
on two simultaneous events: i) adsorption of new material from the
subphase into the newly opened interface and ii) re-extension of
compressed/collapsed structures to re-form a monolayer ﬁlm. HA
might promote adsorption but impair re-extension, both results as a
consequence of its effect on the structure/rheology of the bulk
subphase. The better performance of the CLM mixture, compared
with SLM ﬁlms, in the presence of HA, could be a consequence of
the favorable dynamic behavior of the more ﬂuid lipid mixture under
the rheological restrictions imposed by the polymer.
Lipid mixtures were used that differed in complexity and
represent in part the lipid composition of native surfactant [45].
These relatively simple mixtures were selected based on their
potential use in developing new therapeutic formulations. The
amount of SP-B and SP-C used approximates the concentrations
found in native surfactant, and is more than double those found in
therapeutic surfactants now available [45]. The concentrations of
dextran, PEG and HA are within the range of those that have been
found effective in other in vitro and in vivo experiments [15,17,14,19].
The concentration of surfactant phospholipid used was 1.25 mg/mL, a
limit imposed by the use of a pulsating bubble surfactometer. The
serum protein concentration used was 290 to 5220 μg/mL giving a
range of serum protein to phospholipid ratios from less than 1:4 to
greater than 4:1. For native surfactant, the ratio of serum protein to
phospholipids for inhibition was less than 3:1, while the optimal
mixtures of combined polymers and surfactant proteins were not
inhibited with ratios greater than 4:1 indicating less susceptibility to
inhibition for these semisynthetic mixtures compared with native
surfactant.
The concentration of phospholipid in commercial therapeutic
surfactants is 25 mg to 80 mg/mL. Extrapolation from our results
would suggest that inhibition of 1 mL of these full strength mixtures
would occur with about 100 mg/mL of serum protein. Estimates of
total serum protein in alveolar lung ﬂuid in patients with ARDS range
from 10 to 100 mg/mL [46]. At the low end of this range, the serum
protein to phospholipid ratio is about 1:5, comparable to the low end
of the serum range we studied. At the high end, the ratio would be
about 2:1, a factor of two less than for our best mixtures. That is, the
mixtures with combined polymer and both surfactant proteins would
not be inhibited until at least 200 mg/mL serum protein is present.
These estimates suggest the relevance of our in vitro results to
possible pathologies existent in alveoli during lung injuries only one
of which may involve inﬂux of serum [47].
Given the extensive results from the comparisons of lipid,
surfactant protein, and polymer combinations described above,
more focused experiments with a few selected surfactant/polymer
combinations using captive bubble surfactometry with much higher
surfactant concentrations [34] will be useful. These studies are in
progress with the aim of providing further information on the
mechanisms bywhich polymer addition counteracts serum inhibition.
5. Conclusions
Inhibition of surfactant lipid mixtures was maximally reduced by
the addition of HA and either dextran or PEG in the presence of SP-B
and SP-C with results superior to those of whole native surfactant. The
choice of lipid composition was found to depend on the polymer
added, with single non-ionic polymers favoring the simple mixture
and those with HA favoring the more complex, probably more
dynamic, lipid formulation. The more complex mixture with surfac-
tant proteins but no polymer also gave better results than the simple
lipid mixture. Our experiments with different concentrations of
polymers, surfactant proteins, and lipids suggest that new “recipes”
for therapeutic surfactants may optimize adsorption and compress-ibility while not impairing readsorption during ﬁlm expansion. The
resulting lipid/protein/polymer preparations may be less prone to
inhibition and therefore more efﬁcacious for treatment of conditions
such as ARDS. These ﬁndings also point to the importance and
necessity of pursuing in vivo studies to see if these results translate
into similar ones in animal models.
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